Real world patients with severe eosinophilic asthma show the same good outcomes with mepolizumab as seen in clinical trials – with a particular group of ‘super responders’ with a T2 phenotype, an Australian study has shown. A registry based study found that the anti-IL5 treatment reduced severe exacerbations, hospitalisations and improved asthma symptoms, quality of ...
Mepolizumab ‘super responders’ seen in severe eosinophilic asthma
By Michael Woodhead
24 Mar 2020